bioRxivMicrobiology
Correlated transcriptional responses provide insights into the synergy mechanisms of the furazolidone, vancomycin and sodium deoxycholate triple combination in Escherichia coli
Abstract
Effective therapeutic options are urgently needed to tackle antibiotic resistance. Furazolidone (FZ), vancomycin (VAN), and sodium deoxycholate (DOC) show promise as their combination can synergistically inhibit the growth of, and kill, multidrug-resistant Gram-negative bacteria that are classified as critical priority by the World Health Organization. Here, we investigated the mechanisms of action and synergy of this drug combination using a transcriptomics approach in the model bacterium Escherichia coli. We show that FZ and DOC elicit highly similar gene perturbations indicative of iron starvation, decreased respiration and metabolism, and translational stress. In contrast, VAN induced envelope stress responses, in agreement with its known role in peptidoglycan synthesis inhibition. FZ induced the SOS response consistent with its DNA damaging effects, but we demonstrate that using FZ in combination with the other two compounds enables use of lower dosages and largely mitigates its mutagenic effects. Based on the gene expression changes identified, we propose a synergy mechanism where the combined effects of FZ, VAN, and DOC amplify damage to Gram-negative bacteria while simultaneously suppressing antibiotic resistance mechanisms. ImportanceSynergistic combinations of existing antibacterials against multidrug-resistant "superbugs" are an alternative strategy to costly and arduous development of novel antibacterial molecules. The synergistic combination of nitrofurans, vancomycin and sodium deoxycholate shows promise in inhibiting and killing multidrug-resistant Gram-negative bacteria. We examined the mechanism of action and synergy of these three antibacterials, and proposed a mechanistic basis for their synergy. Our results highlight much needed mechanistic information necessary to advance this combination as a potential therapy.
- organism: E. coli
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vitro synergy between Sodium Deoxycholate and Furazolidone against Enterobacteria via Inhibition of Multidrug Efflux Pumps
V. V. H. Le, C. Olivera, … J. Rakonjac·bioRxiv·Jan 11, 2019
- Mutations in the riboflavin biosynthesis pathway confer resistance to furazolidone and abolish the synergistic interaction between furazolidone and vancomycin in Escherichia coli.
Hannah Wykes, Vuong Van Hung Le, Jasna Rakonjac·Microbial GenomicsPeer-reviewed·Feb 11, 2025
- In-vitro resensitization of multidrug resistant clinical isolates of Enterococcus faecium and faecalis through phage-antibiotic synergy
Pooja Ghatbale, Govind Prasad Sah, … David T. Pride·Antimicrobial Agents and ChemotherapyPeer-reviewed·Dec 19, 2024
- A Mechanistic Approach to Optimize Combination Antibiotic Therapy
Fabrizio Clarelli, Pierre Ankomah, … Pia Abel zur Wiesch·BiosystemsPeer-reviewed·Dec 24, 2024
- Suppression of bacterial cell death underlies the antagonistic interaction between ciprofloxacin and tetracycline in Escherichia coli
James Broughton, Achille Fraisse, Meriem El Karoui·bioRxiv·Apr 18, 2024
- Potentiating antibiotic treatment using fitness-neutral gene expression perturbations
Peter B. Otoupal, Keesha E. Erickson, … Anushree Chatterjee·bioRxiv·Aug 15, 2019